On July 1, 2020 Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, reported that clinical data from the Phase 1/2 open-label study of EDP1503, in combination with pembrolizumab, in patients with advanced metastatic microsatellite stable colorectal carcinoma (MSS CRC), triple-negative breast cancer (TNBC), and checkpoint inhibitor relapsed tumors, will be presented at the ESMO (Free ESMO Whitepaper) World Congress on Gastrointestinal Cancer Virtual Meeting being held July 1 – 4, 2020 (Press release, Evelo Biosciences, JUL 1, 2020, View Source [SID1234561615]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition to data in MSS CRC patients, the poster reported preliminary data on 11 TNBC patients (8 on high dose and 3 on low dose EDP1503). An overall response rate (ORR) of 25% (2/8) and a disease control rate of 37.5% (3/8) were observed across all TNBC subjects receiving high dose EDP1503. ORR was 33% (2/6) amongst response-evaluable patients on the high dose, with 2 patients awaiting first response assessment. Historic studies of anti-PD-1 monotherapy in heavily pretreated TNBC patients have yielded an ORR of 5-10%. The study continues enrollment in TNBC, and further data from this cohort will be available in 4Q 2020.
Details of the poster are as follows:
Title: EDP1503 induces antitumor responses via gut-mediated activation of both innate and adaptive immunity
Poster Session Date: July 1-4, 2020
Abstract ID: P-325
Category: Clinical Colon Cancer
Authors: Loise Francisco-Anderson, PhD; Shamira Shariffudin; Humphrey Gardner, MD; Michael Goldberg, PhD; Shubhra Kashyap, MS; Mary Abdou; Chris Davitt, PhD; Shannon Argueta, PhD; Pooja Parameswaran, MS; Peter Sandy, PhD; Holly Ponichtera, PhD; Mark Carlson; Maria Sizova, PhD; Valeria Kravitz; Erin Troy, PhD; Sam Andrewes, MS; Johanna C. Bendell, MD; Judy S. Wang, MD; Susanna V. Ulahannan, MD; Michael Chisamore, PhD; Mark Bodmer, PhD; and Duncan McHale, MD
The poster is available online on the ESMO (Free ESMO Whitepaper) conference website, as well as on the Evelo website, under the "publications" tab.